Victoria Socha

DocwireNews

Kidney Week 2020Patients with chronic kidney disease (CKD) with type 2 <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/alcohol-consumption-type-2-diabetes-hypertension/">diabetes</a> are at high risk for cardiovascular events. However, according to researchers there are few data available on the excess risk of kidney events in patients CKD and diabetes compared with those without diabetes.During a virtual poster at ASN Kidney Week 2020, Alyshah Abdul Sultan, MSc, PhD, and colleagues reported on results of an analysis of data from DISCOVER-CKD, an international observational study examining real-world management of CKD. The <a href="https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3443369">poster</a> was titled Defining the Risk of Adverse Kidney Outcomes in CKD Patients with Type 2 Diabetes in the DISCOVER-CKD Cohort.DISCOVER-CKD encompasses large retrospective electronic medical records (EMRs) and claims data between 2008 and 2020. The current analysis examined data from US-based Limited Claims and Electronic Health Record (LCED) (IBM Health, Armonk, New York) and TriNetX (hospital-based EMR).The analysis identified patients with CKD, defined as estimated glomerular filtration rate (eGFR) &lt;75 mL/min/1.73 m2, &ge;18 years of age with more than one record of urine albumin to creatinine ratio (UACR). Index was defined as the second eGFR measurement. Diabetes status was ascertained any time prior to the index date. The risk of kidney outcomes, defined as decline in eGFR of 50% or more or end-stage kidney disease, was compared between patients with and without type 2 diabetes at 5 years of follow-up.Compared with the cohort without diabetes, those with diabetes had slightly higher incidence rates of adverse renal outcomes (LCED: 2.7% vs 2.3% per year; TriNetX: 1.8% vs 1.2% per year). Following adjustment for confounders, there was no increased risk of adverse renal outcomes in patients with CKD and type 2 diabetes compared with those with CKD and no type 2 diabetes in LCED: hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.81-1.43. In the TriNetX database, there was a 34% increased risk of adverse renal outcomes in the cohort with diabetes compared with those without diabetes (HR, 1.34; 95% CI, 1.11-1.62).In summary, the researchers said, &ldquo;There is an excess risk of adverse renal outcomes in CKD patients with type 2 diabetes compared with those without type 2 diabetes. This is explained to a large extent by conventional risk markers in LCED but not completely in TriNetX. Both groups (type 2 diabetes and non-type 2 diabetes) should be managed proactively to reduce the risk of poor clinical outcomes.&rdquo;Source: Abdul Sultan A, Nolan S, Carrero JJ, et al. Defining the excess risk of adverse kidney outcomes in CKD patients with type 2 diabetes in the DISCOVER-CKD cohort. Abstract of a poster presented at the American Society of Nephrology virtual Kidney Week 2020 (Abstract PO0436), October 22, 2020. Funding for this poster was provided by AstraZeneca.

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

Risk of Adverse Renal Outcomes in CKD Patients with Diabetes in DISCOVER-CKD

Chronic Kidney Disease

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe